Discontinuing Drug Treatment in HFrEF, Race and Sacubitril/Valsartan Use in HF, Systolic BP Polygenic Risk Score Treatment Responses
In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart failure and reduced ejection fraction (HFrEF). He then explores the effect of race and sacubitril/valsartan use in HF patients documented in a pooled analysis of the PARADIGM-HF and PARAGON-HF trials. Finally, Dr. Eagle discusses the utility of systolic blood pressure (BP) polygenic risk scores and the treatment response in people with hypertension.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Heart Failure and Cardiomyopathies, Prevention, Vascular Medicine, Statins, Acute Heart Failure, Hypertension, Acute Coronary Syndromes
Keywords: EaglesEyeView, Heart Failure, Heart Failure, Reduced Ejection Fraction, Diuretics, Drug Therapy, Angioedema, Race Factors, Renin-Angiotensin System, Valsartan, Blood Pressure, Chlorthalidone, Hypertension, Risk Assessment
